Diffuse Large B-Cell Lymphoma, NOS · line 1 · Rituximab + CHOP (R-CHOP), 6 cycles
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-R-CHOP |
| ID | IND-DLBCL-RENAL-FAILURE-MOD-RCHOP |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-DLBCL-NOS |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Special-population indication for DLBCL + severe CKD. Reference REG-R-CHOP used as proxy with dose modifications described in rationale. Multidisciplinary management essential.
Used By
No reverse references found in the YAML corpus.